Fisher & Paykel Healthcare Full Year 2025 Earnings: EPS Beats Expectations

Fisher & Paykel Healthcare (NZSE:FPH) Full Year 2025 Results

Key Financial Results

• Revenue: NZ$2.02b (up 16% from FY 2024).
• Net income: NZ$377.2m (up 185% from FY 2024).
• Profit margin: 19% (up from 7.6% in FY 2024). The increase in margin was driven by higher revenue.
• EPS: NZ$0.64 (up from NZ$0.23 in FY 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Fisher & Paykel Healthcare EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.3%.

Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Oceania.

Performance of the market in New Zealand.

The company's shares are down 4.2% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Fisher & Paykel Healthcare's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.